TIME IS THE KEY
IN CANCER DIAGNOSIS

We create the future of fighting cancer and giving oncologists technology to increase patients survival rate.
One core platform technology: wide scale-up opportunities and applications. One vision: increase cancer cure rate by 30% by 2030

Read more

About inProbe

Nowadays millions of people die each year from cancer. It’s a medical professionals to save lives of patients worldwide. At the same time the future of cancer therapies is gaining trust, but their efficiency strictly depends on proper and real-time targeted tumor biology diagnostics, which doeas not exist today. That’s why we’ve invented and developed inPROBE, a platform technology which links targeted therapies with targeted diagnostics. Our technology will reduce diagnosis time, increase precision and effects of innovative cancer treatments. It can be used both in cancer diagnostics and therapies monitoring in real time and in natural state thus giving medical professionals previously unavailable fast and efficient tools.

PERSONALIZED TARGETED POINT-OF-CARE DIAGNOSTICS

HELPING ONCOLOGISTS TO IDENTIFY THE RIGHT PATIENTS WHO
BENEFIT THE MOST FROM INNOVATIVE TARGETED TREATMENTS

PATIENTS WELLBEING

Less pain. No waiting time.
Immediate presonalized targeted treatment introduction lowering high stress

IN-VIVO EXAMINATION AND REAL TIME RESULTS

No tissue biopsy.
Results in minutes

HIGH SENSITIVITY

No tumor infraction benefiting with no CANCER METASTASIS.
Enough to get close to the tumor with USG guidance

NUMEROUS SCALE-UP POSSIBILITIES

Most cancer biomarkers
Real-time drug delivery in SITU monitoring
Surgical oncology
Infectious diseases and many others

OBJECTIVE RESULTS

Numerical results
No more false results

How it works

Disruptive 6-micron opto-biological platform technology. Merging fiber optics, bio tech and engineering in a single needle. In essence putting the biology diagnostics tests at the tip of the fiber Microprobe.

Single- cell resolution Microprobe HER2 tumor biomarker in breast cancers as first in-human clinical application (phase 2 of clinical trials running)

Shorten tumor markers testing from several days or weeks to several minutes, without painful tissue biopsy and laboratory waiting time.

All the data gathered during procedure is transferred via fiber optics into the multi- purpose detecting device. Then the data is calculated using speci c algorithms and presented to the oncologist as a diagnostic result – a numerical gure with exact level of tested components (e.g. HER2 cancer biomarker).

During the cancer therapies inProbe will be able to measure active ingredient level (f.e. Trastuzumab) in cancer tumor cells, thus supporting & improving the efficiency of modern targeted cancer therapies and patients’ well-being.

quote

SDS-MicroProbe can be a groundbreaking solution to overcome problems in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am convinced that such solution would find several applications in research as well as in future cell therapies in the cancer area.
Hematologist/Oncologist M.D. PhD with several years of scientific experience at NIH Bethesda, MD, USA
quote

There is an unmet need to study biolog- ical processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyz- ing key intracellular parameters that indicate the functionality of a cell. The SDS- MicroProbe has the potential to substantially advance our ability to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficacy of interventions.
Proffesor, PhD of Harvard Medical School Boston, MA, USA

About SDS Optic

At SDS Optic we strive to make a difference in the world. We connect vast medical knowledge with technical skills to create technologies that can revolutionize global healthcare. Our team consists of renown experts in biology, optoelectronics, medicine, advanced technologies, chemistry, biomedical engineering and related sciences. SDS Optic’s strategy is to discover, develop, produce and commercialize our unique diagnostics and monitoring tools on a global scale. We want to develop life saving innovations which can help medical professionals in real-time. Our team concentrates on assisting healthcare with faster and less painful diagnostics tools as well as supporting targeted, effective treatment procedures.


Timeline

The beginning
 2013-2014

First trials of
inPROBE on
animal cells

SDS Optic develops 6 micron diameter optical fibre tip: the base technology of improve

First presentations of the inprobe technology in the USA and Europe, receiving positive testimonials from KOLs

2015

The National Centre of Research and Development (NCBiR) grants €2,6M to cover all R&D expenses

2016

First in vitro testing results

Technology is validated and capable to measure different cancer biomarkers in real time

2017

SDS Optic applies for 2 independent patents in PCT worldwide procedure

Pre clinical - Pre-Clinical testing on mouse and rat models
SME - grants almost €4M funding to run clinical trials and implement commercialisation strategy

2018

R&D Centre kick off in Lublin. Team of Biology, Chemist, Physics & Engineering PhDs’ and MScs’

INNOventure VC fund invests €750K into R&D CapEx and reserch activities

2019

ContentFinal stage of Pre-Clinical trials on rat models with human HER2 overexpressing breast cancer cell lines delivered from living cancer Patients

SDS Optic Ltd. becomes SDS Optic Inc.
First technology scale up opportunities in vitro studies
Kicking off Clinical Trials with ethical committee & regulatory approvals granted
Ongoing Clinical Trials for HER2+ Breast Cancer diagnostics application

Technology Scale Up

Pre-IPO Series A funding
Introducing new long term company strategy focusing on R&D, platform technology Scale Up and M&A of Lifesaving Innovations

2021

Clinical trials completion

CE Mark and ISO13485 Certification

IPO and long term enterprise value building for shareholders
Wide Core Technology Applications - new tumor cancer, endoscopy app, therapies monitoring, surgical oncology

2022

FDA & EMA Approvals for HER2+ Breast Cancer diagnostics application
Market Go Live

Long Term enterprise value delivery for shareholders

Global Organization with at least 2 R&D Centres overseas


Core team


Magdalena Staniszewska, Ph.D.
linkedin mail
Marcin Staniszewski, Msc.
mail
Mateusz Sagan, MBA
linkedin mail
Przemysław Kopyto, M.D.
linkedin mail
Development and commercialization of inProbe by SDS Optic supported by:

partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic

Website design co-financed under the European Regional Developent Fund